Clinical Trial Update: Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

ACE-86225106 is being studied in Phase 1/2 for advanced solid tumors with ongoing recruitment; the study includes BRCA1/BRCA2 mutation-associated cancers, inclu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ovarian Cancer
• Prostate Cancer

Drugs mentioned

• ACE-86225106

Snippet

Sponsor: Acerand Therapeutics (Shanghai) Limited | Conditions: Solid Tumor, Adult, BRCA1 Mutation | Phase 1, Phase 2 | Status: RECRUITING